51 related articles for article (PubMed ID: 38476366)
1. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with
Rekowska A; Rola P; Wójcik-Superczyńska M; Chmielewska I; Krawczyk P; Milanowski J
Curr Oncol; 2022 May; 29(5):3531-3539. PubMed ID: 35621675
[TBL] [Abstract][Full Text] [Related]
3. Remarkable response to third-generation EGFR-TKI plus crizotinib in a patient with pulmonary adenocarcinoma harboring EGFR and ROS1 co-mutation: a case report.
Wu Z; Zhang Z; Zhang D; Li Z
Front Oncol; 2024; 14():1357230. PubMed ID: 38476366
[TBL] [Abstract][Full Text] [Related]
4. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
5. EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient.
Ju L; Han M; Zhao C; Li X
Lung Cancer; 2016 May; 95():94-7. PubMed ID: 27040858
[TBL] [Abstract][Full Text] [Related]
6. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
7. Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
Wang Y; Chen Z; Han X; Li J; Guo H; Shi J
Oncologist; 2021 Mar; 26(3):178-181. PubMed ID: 33000474
[TBL] [Abstract][Full Text] [Related]
8. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Jorge SE; Schulman S; Freed JA; VanderLaan PA; Rangachari D; Kobayashi SS; Huberman MS; Costa DB
Lung Cancer; 2015 Dec; 90(3):369-74. PubMed ID: 26791794
[TBL] [Abstract][Full Text] [Related]
9. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.
Li D; Jiang H; Jin F; Pan L; Xie Y; Zhang L; Li C
Genes Genomics; 2023 Jan; 45(1):93-102. PubMed ID: 36445572
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in the management of lung cancer: changing the practice of thoracic oncology.
Melichar B
Clin Chem Lab Med; 2023 Apr; 61(5):906-920. PubMed ID: 36384005
[TBL] [Abstract][Full Text] [Related]
11. Synchronous driver gene alterations (EGFR L858R, T790M, and ROS1) rearrangements in a patient with early-stage lung adenocarcinoma.
Masago K; Kuroda H; Takahashi Y; Oya Y; Sasaki E; Sakakura N; Matsushita H
Cancer Genet; 2022 Nov; 268-269():124-127. PubMed ID: 36332423
[TBL] [Abstract][Full Text] [Related]
12. EGFR signaling pathway as therapeutic target in human cancers.
Levantini E; Maroni G; Del Re M; Tenen DG
Semin Cancer Biol; 2022 Oct; 85():253-275. PubMed ID: 35427766
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).
He J; Huang Z; Han L; Gong Y; Xie C
Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34558640
[TBL] [Abstract][Full Text] [Related]
14. ROS1 Targeted Therapies: Current Status.
Azelby CM; Sakamoto MR; Bowles DW
Curr Oncol Rep; 2021 Jun; 23(8):94. PubMed ID: 34125313
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao M; Jiang T; Liu X; Mao S; Zhou F; Li X; Zhao C; Chen X; Su C; Ren S; Zhou C
J Thorac Oncol; 2021 Aug; 16(8):1267-1288. PubMed ID: 33915248
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
